On the heels of pocketing $30M from Alexion, Stealth Bio says its PhIII was a flop

Two months ago, the BD team at Alexion paid $30 million to buy themselves a front-row seat to Stealth BioTherapeutics’ Phase III on elamipretide, a potential first-in-class drug for mitochondrial disease. But that potential — along with the shares Alexion bought in the deal — have now been badly damaged.

Read the full article here

Related Articles